Purpose The purpose of this study was to evaluate the serum estradiol (E2) per oocyte ratio (EOR) as a function of selected embryology events and reproductive outcomes with IVF. Methods This retrospective analysis included all IVF cycles where oocyte collection and fresh transfer occurred between January 2001 and November 2012 at a single institution. Patients were divided by three age groups (<35, 35-39, and ≥40 years) and further stratified into nine groups based on EOR (measured in pmol/L/oocyte). Terminal serum E2 (pmol/mL) was recorded on day of hCG trigger administration, and fertilization rate, cleavage rate, number of good quality embryos, and reproductive outcomes were recorded for each IVF cycle. Results During the study interval, 9109 oocyte retrievals were performed for 5499 IVF patients (mean = 1.7 cycles/patient). A total of 63.4 % of transfers were performed on day 3 (n = 4926), while 36.6 % were carried out on day 5 (n = 2843). Clinical pregnancy rates were highest in patients with EOR of 250-750 and declined as this ratio increased, independent of patient age. While the odds ratio (OR) for clinical pregnancy where EOR = 250-750 vs. EOR > 1500 was 3.4 (p < 0.001; 95 % CI 2.67-4.34), no statistically significant correlation was seen in fertilization, cleavage rates or number of good quality embryos as a function of EOR. Conclusions Predicting reproductive outcomes with IVF has great utility both for patients and providers. The former have the opportunity to build realistic expectations, and the latter are better able to counsel according to measured clinical parameters. A better understanding of follicular dynamics and ovarian response to gonadotropin stimulation could optimize IVF treatments going forward.
Introduction
Controlled ovarian hyperstimulation is the standard of care in assisted conception units. Two of the principal clinical parameters when following follicle development are serum estradiol (E2) level and follicular diameter as measured by ultrasound. It is of interest to both clinicians and patients alike to predict the response to (and, ultimately, live birth rate following) ovarian hyperstimulation and IVF. Parameters that are known to correlate positively with success in IVF include endometrial thickness and the number of oocytes retrieved [1] [2] [3] . Conversely, negative predictors include advanced maternal age, elevated basal FSH, and low antral follicular count [4] [5] [6] [7] .
While the role of E2 is well documented in the follicular phase, controversy persists regarding its role in the luteal Capsule In the context of clinical IVF, EOR can provide useful information about ovarian response and follicular dynamics.
phase. Previous research has suggested that both low [8, 9] and supraphysiologic [10, 11] serum levels of E2 are negative predictors of clinical pregnancy after embryo transfer in IVF cycles.
It has been hypothesized that lower serum E2 levels represent hormonally dysfunctional developing follicles, which, in turn, luteinize poorly when exposed to hCG. Oocytes derived from such follicles often have poor fertilization [12] . In oocyte donation, it has been shown that high E2 levels are associated with impaired endometrial receptivity without affecting embryo quality [13] . Loumaye et al. [14] studied serum E2 level on day of hCG administration and the number of oocytes retrieved in patients undergoing long GnRH-agonist suppression. They found the estradiol:oocyte ratio (EOR) to be a reliable indicator for IVF success, with the highest pregnancy rates observed among patients with EOR of 70-140 pg/mL. Yang et al. [15] showed that patients undergoing the flare GnRH-agonist protocol with elevated EOR demonstrated lower pregnancy and implantation rates.
Orvieto et al. [16] found that while EOR cannot predict success of a GnRH-agonist protocol, for patients undergoing a GnRH-antagonist protocol EOR within 100-200 pg/mL range offers the best likelihood of a positive outcome.
While it is clear that elevated EOR denotes disordered folliculogenesis, the limited sampling in prior studies has made meaningful clinical conclusions difficult to develop. In the current investigation evaluating more than 9000 IVF cycles performed at a single institution, we aimed to examine IVF outcome as a function of EOR to contribute an original dataset to the study of this issue.
Methods
This retrospective analysis reviewed data on all patients who underwent IVF at a major European referral center (The HARI Unit/Rotunda Hospital; Dublin, Ireland) between January 2001 and December 2012. As this research was a retrospective medical record audit and did not involve any direct patient contact, it was considered exempt from review by the Ethics Committee of Rotunda Hospital, Dublin. Patient records were divided into three categories: age <35, 35-39, and ≥40 years old, and further sub-divided into nine groups based on EOR:
1. <250 pmol/L/oocyte 2. 250-500 pmol/L/oocyte 3. 500-750 pmol/L/oocyte 4. 750-1000 pmol/L/oocyte 5. 1000-1250 pmol/L/oocyte 6. 1250-1500 pmol/L/oocyte 7. 1500-1750 pmol/L/oocyte 8. 1750-2000 pmol/L/oocyte 9. >2000 pmol/L/oocyte Database accuracy was validated by multiple sources of ascertainment for key variables, and a review of individual medical records was performed if inconsistencies arose.
As previously described [16, 17] , all IVF patients received pituitary downregulation for 12-14 days with either buserelin acetate (Suprecur, Aventis; Dublin, Ireland) 1.2 mg/6 h daily starting on day 1 or 2 of menses, or triptorelin (Decapeptyl SR, Ipsen; Dublin, Ireland) in a dose of 3 mg IM × 1. Pituitary suppression was confirmed by serum E2 levels (<150 pmol/ L) and ultrasound scan. Real-time transvaginal ultrasound was performed using the GE LOGIC 200 ProSeries (Samsung GE Medical Systems, Korea) with a 6.5 MHz vaginal probe. Follicular diameters were calculated from the mean of two perpendicular diameters.
Serum oestradiol E2 levels were measured by timeresolved fluoroimmunoassay on an AutoDELFIA 1235 Automatic Immunoassay System (Turku, Finland). If the patient was not adequately suppressed, GnRH-a administration was continued × 1 week at double the dose and oestradiol E2 level repeated. After confirmation of pituitary down-regulation, gonadotrophin-controlled ovarian stimulation with either follitropin beta (Puregon, Organon; Oss, Netherlands) or urinary-derived product (Menopur, Ferring; Dublin, Ireland) was commenced. Starting dose was determined according to the day 3 follicle-stimulating hormone (FSH) level. For patients on their first cycle where their basal day 3 FSH was <8.5 U/ L, 200 IU rFSH or 225 IU human menopausal gonadotropin (hMG) were used for initial dosing, whereas if the day 3 FSH was ≥8.5 U/L, 400 IU rFSH or 450 IU hMG was administered. For patients in subsequent cycles of treatment, the maximum dose in the previous cycle was used. These regimens were prescribed × 6 days, and on day 7 the ovarian response was assessed by ultrasound scan and E2 levels.
Periodic ultrasound and serum E2 monitoring was used to determine the timing of hCG (Pregnyl, Organon; Oss, Netherlands) administration. Cycles were cancelled on d8 if serum E2 levels were <300 pmol/L, or if <3 follicles were present. When the ovarian response was deemed adequate, the same daily dosage was continued with a monitoring visit on day 10, and daily visits from then onwards. If excessive response was evident on day 7 (E2 > 3000 pmol/L or more than six follicles in each ovary), the gonadotrophin dose was reduced and daily monitoring with transvaginal ultrasound and E2 levels was instituted. In some cases where rapid elevation of levels occurred, coasting was employed.
Once the leading three follicles reached an average diameter of 18 mm or more, hCG 10,000 IU IM was administered. In cases where coasting was employed, hCG was administered after E2 levels plateaued or started to fall. Transvaginal oocyte recovery was performed 34 h later under midazolam (Hypnovel, Roche; London, UK) and fentanyl citrate (Sublimaze, Janssen-Cilag; High Wycombe, UK) i.v.-monitored sedation. All surgeons performing oocyte retrievals were carefully audited and trained to the same standard; follicular flushing was used to reduce the risk of failure of oocyte retrieval. Regarding fertilization method, criteria for ICSI included non-ejaculated sperm, total sperm count <2.5 M/mL, motility <20 %, and normal forms morphology <30 % (WHO criteria). ICSI was also performed when fertilization failure was documented in a prior cycle. All serum E2 measurements were recorded from the same laboratory using uniform equipment where assay sensitivity was 5 pmol/L and mean intraassay CV was 9 %.
Fresh transfer of two embryos (otherwise three embryos if available at age >35 years) was performed routinely on day 3 or day 5 after oocyte retrieval. This review did not include any frozen embryo transfer cycles.
Criteria for ICSI included non-ejaculated sperm, total sperm count <2.5 M/mL, motility <20 %, normal forms morphology <30 % (WHO criteria). ICSI was also performed when fertilization failure was documented in a prior cycle. All serum E2 measurements were recorded from the same laboratory using uniform equipment where assay sensitivity was 5 pmol/L and mean intra-assay CV was 9 %.
When transfer did not occur, no luteal support was given. Luteal support used vaginal progesterone pessaries 200 mg, p.v., twice daily (Cyclogest, Actavis; Devon, UK) or gel 1.125 g, p.v., twice daily (Crinone 8 %, Serono; London, UK) for 14 days post transfer. If the number of oocytes was less than 10, hCG (Pregnyl, Organon; Oss, Netherlands) 5000 IU, IM × 2 (day of transfer and 2 days after) was given. When more than 10 oocytes were collected, luteal phase hormonal support was with progesterone only.
The International Committee for Monitoring Assisted Reproductive Technology (ICMART) and WHO revised glossary of ART terminology for IVF/ICSI outcomes were used, such that clinical pregnancy was defined as a pregnancy diagnosed by ultrasound visualization of one or more gestational sacs or definitive clinical signs of pregnancy, including 
Results
A total of 9,109 oocyte retrievals were performed for 5,499 patients during the study interval. The median (±SD) patient age was 35 ± 2.9 (range 18-47) years, mean serum E2 on day of hCG administration was 6950.7 (±3,865) pmol/L, and mean number of oocytes retrieved was 10.7. Of 9109 cycles, clinical pregnancy was achieved in approximately 32 %. Table 1 summarizes demographic and cycle characteristics according to EOR. In this population 63.4 % of transfers were performed on day 3 (n = 4926), while 36.6 % were carried out on day 5 (n = 2843). EOR increased dramatically for IVF patients above age 40. Furthermore, mean peak serum E2 level at hCG administration was inversely related to patient age; this was most notable for patients above age 33 (see Figs. 1 and 2 ). 
Oocyte maturation
The percentage of oocytes at metaphase II was lowest (72.0 %) among patients with EOR < 250, and was highest in the group where EOR was greatest (81.8 % when EOR = 1750-2000, 81.9 % when EOR > 2000) as summarized in Table 2 . Of note, the proportion of germinal vesicle stage oocytes was maximal in the group where EOR was lowest (11.2 % when EOR < 250).
Fertilization rates
When fertilization rates were assessed with respect to EOR, a direct relationship was apparent: the lowest fertilization rates were found in the group where EOR was lowest (see Table 3 ), and this parameter increased with increasing EOR-until the EOR reached > 2000, at which point the fertilization rate declined. This pattern was also apparent for ICSI cases, with lowest fertilization measured when EORs were at the extremes of our reference groups (i.e., <250 and >2000). Moreover, the fertilization failure rate was highest when EOR was maximal >2000 (15.2 %).
Clinical pregnancy
As shown in Table 4 , clinical pregnancy rates per egg retrieval in this population reached a peak at 36.1 % when EOR was 250-500 (p < 0.05, OR 1.19) and were lowest when EOR was highest (12.6 and 11.9 %) when serum E2 levels were 1750-2000 and >2000 pmol/L, respectively (p < 0.05, OR 1.37).
EOR 250-750 vs. >1000
When reproductive outcome was evaluated as a function of EOR of 250-750 vs. EOR >1000, it was observed that, irrespective of age, the former ratio was more likely to result in clinical pregnancy with OR's of 1.66, 1.94, and 1.82 for age groups <35, 35-39, and >40 years, respectively (see Table 5 ).
Overall, patients in our study group with an EOR of 250-750 were twice as likely to achieve clinical pregnancy compared to patients with an EOR > 1000 (OR 2.04, 95% CI 1.80-2.31). Tables 6 and 7 , while observed endometrial thickness measurements are presented in Table 8 . Data for entire study population (not stratified by patient age) is shown in shaded cells OR odds ratio, CI confidence interval
Discussion
The success of ART depends on several factors including female age, embryo quality, and endometrial receptivity. While E2 levels can serve as a marker of granulosa cell function and modulates endometrial development, studies of the relationship between serum E2 and pregnancy rates from IVF have yielded inconsistent results [8, [16] [17] [18] . In this retrospective study, the largest of its kind ever undertaken in Ireland, several observations are notable and provide support for previous investigations. We have demonstrated that serum E2 levels measured on the day of hCG administration are inversely proportional to patient age, and that the most marked decline is seen after the age of 33 years. Likewise, with increasing patient age, the quantity of oocytes retrieved decreases. In addition, as maternal age increased, a linear increase in EOR was observed as the number of oocytes retrieved declined (in contrast to simple E2 level measured on day of hCG administration).
Our research also contributes further evidence supporting what may be predicted during IVF: relatively low quality oocytes are more likely to be retrieved as EOR rises. Indeed, the frequency of immature oocytes is greatest when EOR is <250, where the highest percentage of oocytes at germinal vesicle stage maturity and the lowest percentage of oocytes reaching metaphase II are present. Our study also illustrates that the proportion of germinal vesicle stage cells retrieved during IVF increases when EOR is >1750 (although in this group, the percentage of oocytes reaching metaphase II stage did not similarly correlate, e.g., 81.8 % when EOR 1750-2000, and 81.9 % when EOR >2000). These data also show that, independent of patient age, clinical pregnancy rates correlate with the EOR. We suggest that an optimal EOR is in the range of 250-750 which resulted in a CPR of 35.8 %, compared to the mean clinical pregnancy rate of ∼32 % overall.
Early follicular phase E2 levels have been used to predict the outcome of COH cycles, such that serum E2 levels <100 pg/mL appear to have worse outcomes than those >100 [9] . While some authors have shown that EOR is important in a successful COH cycle [14, [18] [19] [20] , generalizations have been tempered by limited sampling. Thus, it is not particularly surprising that an Bideal^or Btarget^EOR during IVF remains elusive. In the first study describing EOR in this ICSI intracytoplasmic sperm injection, GnRH gonadotropin releasing hormone setting, Loumaye et al. [14] suggested that the optimal EOR was 70-140 pg/mL per oocyte (250-500 pmol/oocyte). Pena et al. [21] reported improved embryo quality with increasing E2 levels, resulting in improved pregnancy rates with IVF. Ozdegirmenci et al. [22] examined serum E2 level with respect to number of mature follicle and, while the results were not statistically significant, higher clinical pregnancy rates were observed when the serum E2:follicle ratio exceeded 540 pg/mL, while pregnancy results were impaired when the serum E2:follicle ratio was <250 pg/mL.
There are some weaknesses associated with our research, which should be acknowledged. For example, although this work reports on the largest IVF patient cohort ever tabulated from a single institution in Ireland (and possibly worldwide), it is limited in being a retrospective analysis. Also, due to constraints in data recording, how specific COH protocols may have affected serum E2 and various embryology parameters could not be assessed in this investigation. Moreover, it would have been interesting to correlate outcomes with serum E2 values throughout the follicular recruitment interval (not just on day of hCG administration), but unfortunately these data points were not uniformly recorded for all study patients. While we were able to capture data on endometrial dynamics near the time of fresh embryo transfer, other characteristics (e.g., homogeneous vs. trilaminar configuration) were not specifically tabulated. Finally, having either morphokinetic or cytogenetic data (i.e., from preimplantation screening) on embryos would also have added a further dimension to our research, but this technology was not available during the entire study interval.
In summary, we believe that EOR data can be a useful adjunct in predicting success rates of an IVF cycle. Additional observational research is needed to better characterize the relationships among serum E2 measurements, ultrasound data, embryo development, and reproductive outcome in IVF.
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